Related Experiment Videos
Anticancer drugs acting against signaling pathways
1Arizona Cancer Center, Tucson, USA.
Current Opinion in Oncology
|November 1, 1995
Summary
This review covers anticancer drugs targeting cellular signaling pathways. While some drugs show early promise and reported toxicities, extensive clinical trials are still needed for these novel cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer cells rely on specific signaling pathways for growth and survival.
- Targeting these pathways with drugs offers a promising strategy for cancer treatment.
- Several classes of signaling inhibitors have been investigated in preclinical and early clinical settings.
Purpose of the Study:
- To review anticancer drugs that target key cellular signaling pathways.
- To summarize the current status of these drugs in cancer patient studies.
- To identify future directions for drug development in this area.
Main Methods:
- Literature review of studies on anticancer drugs targeting signaling pathways.
- Categorization of drugs based on their molecular targets (e.g., protein kinases, ion channels, ras function).
- Analysis of reported clinical trial data, toxicities, and antitumor activity.
Main Results:
- Several drug categories targeting signaling pathways have been studied, including modulators of protein kinase C, inhibitors of protein kinase A, protein tyrosine kinase, and receptor-operated Ca2+ channels.
- Drugs modulating ras function have also been investigated.
- Currently, none of these agents have undergone extensive clinical trials, though toxicities and anecdotal antitumor activity have been reported.
Conclusions:
- Anticancer drugs targeting signaling pathways represent an emerging class of therapeutics.
- Further clinical investigation is required to establish the efficacy and safety of these agents.
- Numerous other signaling-targeted anticancer drugs are in development and awaiting clinical trials.